For biopharma
Biopharma commercial teams need biomarker testing data, not a modeled estimate of it. Voyager shows which providers are testing, alerts you when a result creates an eligible patient, and surfaces the places in the community where testing is not happening at all.
60K
HER2 IHC across tumors
20K
ER/PR in breast
30K
Heme and solid tumor liquid biopsies
20K
Comprehensive genomic solid tumor profiles
A targeted therapy only reaches a patient whose biomarker was tested for and confirmed. By the time that appears in claims data, the treatment decision has usually been made, and the field team learns about the account a quarter after it mattered.
The harder problem is absence. A provider who never orders the test generates no signal at all, so the patients who would have been eligible are invisible in the data your team works from.
01
Segment the market by the markers your brand depends on — ER, PR, HER2, PD-L1 and genomic markers, across single-analyte testing and next-generation sequencing. Work from a list built around your therapy rather than a specialty code.
02
A first order, a confirmed result, a shift in a testing pattern. Voyager flags it against a specific biomarker or ICD-10 code the same day, so the field reaches the provider while the decision is still open.
03
The same view surfaces where testing is not happening. Identify the community providers who are not ordering, so gaps can be closed and precision medicine reaches the patients whose care depends on it.
Tell us the brand, the biomarker and the geography. We will show you the providers, cohorts and triggers Voyager would hand your field team, on data you can check. The target list we build on the call is yours to keep.